Frontline-Treatment Of Acute Lymphoblastic Leukemia (ALL) In Older Adolescents and Young Adults (AYA) Using a Pediatric Regimen Is Feasible: Toxicity Results of the Prospective US Intergroup Trial C10403 (Alliance) Advani, Anjali S. , Sanford, Ben , Luger, Selina , Devidas, Meenakshi ... - ASH - Blood - 2013 Abstract - Secondary - Primary - Leukemia - C10403
Expression and polymorphism (rs4880) of mitochondrial superoxide dismutase (SOD2) and asparaginase induced hepatotoxicity in adult patients with acute lymphoblastic leukemia Alachkar, Houda , Fulton, Noreen , Sanford, Ben , Malnassy, Greg ... - - Pharmacogenomics J. - 2017 Manuscript - Secondary - Primary - Leuk Corr Sci - CALGB-10102
Low-Dose Interleukin-2 Immunotherapy Does Not Improve Outcome of Patients Age 60 Years and Older With Acute Myeloid Leukemia in First Complete Remission: Cancer and Leukemia Group B Study 9720 Baer, Maria R. , George, Stephen L. , Caligiuri, Michael A. ... - - J Clin Oncol - 2008 Manuscript - Secondary - Primary - Leukemia - CALGB-8461 , CALGB-9720
Low-dose interleukin-2 immunotherapy does not improve outcome of patients age 60 years and older with acute myeloid leukemia in first complete remission: Cancer and Leukemia Group B Study 9720 Baer, Maria R. , George, Stephen L. , Caligiuri, Michael A. ... - - J. Clin. Oncol. - 2008 Abstract - Secondary - Primary - Leukemia - CALGB-10201 , CALGB-10502 , CALGB-10503 , CALGB-10603 , CALGB-19808 , CALGB-8525 , CALGB-8923 , CALGB-9022 , CALGB-9222 , CALGB-9420 , CALGB-9621 , CALGB-9720
Maintenance therapy with decitabine in younger adults with acute myeloid leukemia in first remission: a phase 2 Cancer and Leukemia Group B study (CALGB 10503) Blum, William , Sanford, Ben L. , Klisovic, Rebecca ... - - Leukemia - 2017 Manuscript - Primary - Primary - Leukemia - CALGB-10503
Cabozantinib Versus Sunitinib As Initial Targeted Therapy for Patients With Metastatic Renal Cell Carcinoma of Poor or Intermediate Risk: The Alliance A031203 CABOSUN Trial Choueiri, Toni K. , Halabi, Susan , Sanford, Ben L. , Hahn, Olwen ... - - J. Clin. Oncol - 2017 Manuscript - Primary - Primary - GU - A031203
CABOzantinib versus SUNitinib (CABOSUN) as initial targeted therapy for patients with metastatic renal cell carcinoma (mRCC) of poor and intermediate risk groups: results from ALLIANCE A031203 Trial. Choueiri, Toni K. , Halabi, Susan , Sanford, Ben L. , Hahn, Olwen ... - ESMO - - 2016 Abstract - Primary - Primary - GU - A031203
Progression-free survival (PFS) by independent review results from ALLIANCE A031203 trial (CABOSUN): cabozantinib versus sunitinib as initial targeted therapy for patients (pts) with metastatic renal cell carcinoma (mRCC) Choueiri, Toni K. , Hessel, Colin , Halabi, Susan , Sanford, Ben ... - ESMO - Ann Oncol - 2017 Abstract - Primary - Primary - GU - A031203
Cabozantinib versus sunitinib as initial therapy for metastatic renal cell carcinoma of intermediate or poor risk (Alliance A031203 CABOSUN randomised trial): Progression-free survival by independent review and overall survival update Choueiri, Toni K. , Hessel, Colin , Halabi, Susan , Sanford, Ben ... - - Eur. J. Cancer - 2018 Manuscript - Secondary - Primary - GU - A031203
Tumor volume changes on 1.5 tesla endorectal MRI during neoadjuvant androgen suppression therapy for higher-risk prostate cancer and recurrence in men treated using radiation therapy results of the phase II CALGB 9682 study D'Amico, Anthony V. , Halabi, Susan , Tempany, Clare ... - - Int J Radiat Oncol Biol Phys - 2008 Manuscript - Secondary - Primary - GU - CALGB-9682
p53 protein expression status and recurrence in men treated with radiation and androgen suppression therapy for higher-risk prostate cancer: a prospective phase II Cancer and Leukemia Group B Study (CALGB 9682). D'Amico, Anthony V , Halabi, Susan , Vollmer, Robin ... - - Urology - 2008 Manuscript - Secondary - Primary - GU - CALGB-159807 , CALGB-9682
Prognostic and predictive impact of NPM1/FLT3-ITD genotypes as defined by 2017 European LeukemiaNet (ELN) risk categorization from randomized patients with acute myeloid leukemia (AML) treated within the International RATIFY Study (ALLIANCE 10603) Döhner, Konstanze , Thiede, Christian , Jahn, Nikolaus ... - EHA - HemaSphere - 2019 Abstract - Secondary-not-in-original - Primary - Leukemia - Z901101
Prognostic impact of NPM1/FLT3-ITD genotypes from randomized patients treated within the RATIFY/CALGB 10603 (Alliance) Study Döhner, Konstanze , Thiede, Christian , Larson, Richard A. ... - ASH - Blood - 2017 Abstract - Secondary-not-in-original - Primary - Leukemia - CALGB-10603
The prognostic significance of plasma interleukin-6 levels in patients with metastatic hormone-refractory prostate cancer: results from Cancer and Leukemia Group B 9480. George, Daniel J , Halabi, Susan , Shepard, Timothy F , Sanford, Ben ... - - Clin. Cancer Res. - 2005 Manuscript - Primary - Primary - GU - INT-0159
Cabozantinib versus sunitinib for previously untreated patients with advanced renal cell carcinoma (RCC) of intermediate or poor risk: subgroup analysis of progression-free survival (PFS) and objective response rate (ORR) in the Alliance A031203 CABOSUN trial George, Daniel , Hessel, Colin , Halabi, Susan , Sanford, Ben ... - ASCO GU - J Clin Oncol - 2018 Abstract - Secondary-not-in-original - Primary - GU - A031203
A Phase II Study of the Oral VEGF Receptor Tyrosine Kinase Inhibitor Vatalanib (PTK787/ZK222584) in Myelodysplastic Syndrome: Cancer and Leukemia Group B Study 10105 (Alliance) Gupta, Pankaj , Mulkey, Flora , Hasserjian, Robert P. ... - - Invest New Drugs - 2013 Manuscript - Primary - Primary - Leukemia - CALGB-10105
Feasibility of geriatric assessment for older adults with acute myeloid leukemia (AML) receiving intensive chemotherapy on a cooperative group trial: CALGB 361006 (Alliance). Klepin, Heidi D. , Ritchie, Ellen K. , Sanford, Ben L. ... - ASCO - J. Clin. Oncol. - 2014 Abstract - Primary - Primary - Older Adult - CALGB-361006
Geriatric assessment among older adults receiving intensive therapy for acute myeloid leukemia: Report of CALGB 361006 (Alliance). Klepin, Heidi D , Ritchie, Ellen , Major-Elechi, Brittny ... - - J Geriatr Oncol - 2020 Manuscript - Primary - Primary - Older Adult - CALGB-361006
An Analysis of Maintenance Therapy and Post-Midostaurin Outcomes in the International Prospective Randomized, Placebo-Controlled, Double-Blind Trial (CALGB 10603/RATIFY [Alliance]) for Newly Diagnosed Acute Myeloid Leukemia (AML) Patients with FLT3 Mutations Larson, Richard A. , Mandrekar, Sumithra , Sanford, Ben L ... - ASH - Blood - 2017 Abstract - Secondary - Primary - Leukemia - CALGB-10603
Midostaurin reduces relapse in FLT3-mutant acute myeloid leukemia: the Alliance CALGB 10603/RATIFY trial. Larson, Richard A , Mandrekar, Sumithra J , Huebner, Lucas J ... - - Leukemia - 2021 Manuscript - Secondary-not-in-original - Primary - Leukemia - CALGB-10603
Application of multi-state models in cancer clinical trials Le-Rademacher, Jennifer G , Peterson, Ryan A , Therneau, Terry M ... - - Clin Trials - 2018 Manuscript - No-Endpoint - Other - Leukemia - A151732 , CALGB-10603
Management of recurrent prostate cancer after radiotherapy: long-term results from CALGB 9687 (Alliance), a prospective multi-institutional salvage prostatectomy series Mohler, James L. , Halabi, Susan , Ryan, Stephen T. , Al-Daghmin, Ali ... - - Prostate Cancer Prostatic Dis. - 2019 Manuscript - Primary - Long-Term-Followup - GU - CALGB-9687
Randomized Controlled Trial of Early Zoledronic Acid in Men With Castration-Sensitive Prostate Cancer and Bone Metastases: Results of CALGB 90202 (Alliance) Smith, Matthew R. , Halabi, Susan , Ryan, Charles J. , Hussain, Arif ... - - J. Clin. Oncol - 2014 Manuscript - Primary - Primary - GU - CALGB-90202
What determines the outcomes for adolescents and young adults with acute lymphoblastic leukemia treated on cooperative group protocols? A comparison of Children's Cancer Group and Cancer and Leukemia Group B studies Stock, Wendy , La, Mei , Sanford, Ben , Bloomfield, Clara D. ... - - Blood - 2008 Manuscript - Secondary-not-in-original - Meta-Analysis - Leukemia - CALGB-8811 , CALGB-9331 , CALGB-19802 , CALGB-8461 , CALGB-9111 , CALGB-9511
A pediatric regimen for older adolescents and young adults with acute lymphoblastic leukemia: results of CALGB 10403 Stock, Wendy , Luger, Selina M. , Advani, Anjali S. , Yin, Jun ... - - Blood - 2019 Manuscript - Primary - Primary - Leukemia - CALGB-10403
Favorable outcomes for adolescents and young adults (AYA) with Acute Lymphoblastic Leukemia (ALL): Early results of US Intergroup trial CALGB 10403 (Alliance) Stock, Wendy , Luger, Selina , Advani, Anjali , Geyer, Susan ... - ASH - Blood - 2014 Abstract - Primary - Preliminary - Leukemia - CALGB-10403
Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a FLT3 Mutation Stone, Richard M. , Mandrekar, Sumithra J. , Sanford, Ben L. ... - - N. Engl. J. Med. - 2017 Manuscript - Primary - Primary - Leukemia - CALGB-10603
The Addition of Midostaurin to Standard Chemotherapy Decreases Cumulative Incidence of Relapse (CIR) in the International Prospective Randomized, Placebo-Controlled, Double-Blind Trial (CALGB 10603 / RATIFY [Alliance]) for Newly Diagnosed Acute Myeloid Leukemia (AML) Patients with FLT3 Mutations Stone, Richard M. , Mandrekar, Sumithra , Sanford, Ben L ... - ASH - Blood - 2017 Abstract - Secondary-not-in-original - Primary - Leukemia - CALGB-10603
Midostaurin v Placebo plus Daunorubicin/Cytarabine Induction, High-dose Cytarabine Consolidation and Maintenance Therapy in Newly Diagnosed Acute Myeloid Leukemia ( AML) Patients ( pts) age 18-60 with FLT3 mutations: An International Prospective Randomized Placebo-Controlled Double-Blind Trial (CALGB 10603 [Alliance]) Stone, Richard M. , Mandrekar, Sumithra , Sanford, Ben L ... - ASH - Blood - 2015 Abstract - Secondary - Primary - Leukemia - CALGB-10603
High Dose Cytarabine plus Gemtuzumab Ozogamicin for Patients with Relapsed or Refractory Acute Myeloid Leukemia: Cancer and Leukemia Group B Study 19902 Stone, Richard M. , Moser, Barry , Sanford, Ben , Schulman, Philip ... - - Leuk Res - 2011 Manuscript - Primary - Primary - Leukemia - CALGB-19902
A phase 2 study incorporating sorafenib into the chemotherapy for older adults with FLT3-mutated acute myeloid leukemia: CALGB 11001 Uy, Geoffrey L. , Mandrekar, Sumithra J. , Laumann, Kristina ... - - Blood Adv - 2017 Manuscript - Primary - Primary - Leukemia - CALGB-11001
Addition of Sorafenib to Chemotherapy Improves the Overall Survival of Older Adults With FLT3-ITD Mutated AML (Alliance C11001). Uy, Geoffrey L. , Mandrekar, Sumithra , Laumann, Kristina ... - ASH - Blood - 2015 Abstract - Primary - Primary - Leukemia - CALGB-11001
Initial Results Of a Phase II Trial Of Sorafenib Plus Standard Induction In Older Adults With Mutant FLT3 Acute Myeloid Leukemia (AML) (Alliance trial C11001) Uy, Geoffrey L. , Sanford, Ben , Marcucci, Guido , Zhao, Weiqiang ... - ASH - Blood - 2013 Abstract - Primary - Preliminary - Leukemia - CALGB-11001
Long-term outcomes for newly-diagnosed multiple myeloma patients treated with pegylated liposomal doxorubicin and bortezomib: final results of CALGB (Alliance) 10301, a multicentre phase II study Voorhees, Peter M. , Orlowski, Robert Z. , Mulkey, Flora ... - - Br. J. Haematol. - 2015 Manuscript - Primary - Primary - Leukemia - CALGB-10301
Effective asparagine depletion with pegylated asparaginase results in improved outcomes in adult acute lymphoblastic leukemia: Cancer and Leukemia Group B Study 9511 Wetzler, Meir , Sanford, Ben L. , Kurtzberg, Joanne ... - - Blood - 2007 Manuscript - Secondary - Primary - Leuk Corr Sci - CALGB-8461 , CALGB-9511
